Abstract
We investigated the agreement between the jugular bulb (JB) and cerebrospinal fluid (CSF) lactate levels. The study was conducted from July 2021 to June 2023 as a prospective observational cohort study at a single center. The right jugular vein was accessed, and the placement of JB catheter tip was confirmed using lateral cervical spine X-ray. A lumbar catheter was inserted between the 3rd and 4th lumbar spine of the patient. Lactate levels were measured immediately, 24 h, 48 h, and 72 h after ROSC. In patients with a good neurological prognosis, kappa between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.08, 0.36, 0.14, − 0.05 (p = 0.65, 0.06, 0.48, and 0.75, respectively). However, in patients with a poor neurological prognosis, kappa between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.38, 0.21, 0.22, 0.12 (p = 0.001, 0.04, 0.04, and 0.27, respectively). This study demonstrated that JB lactate levels exhibited significant agreement with arterial lactate levels, compared to CSF lactate levels. Therefore, this should be considered when using JB lactate to monitor cerebral metabolism.
Subject terms: Neuroscience, Medical research
Introduction
Cerebral ischemia/reperfusion injury following cardiac arrest (CA) is associated with several processes, including cell energy depletion, ionic pump failure, glutamate release, intracellular calcium influx, and release of reactive oxygen species and free radicals1–4. These processes lead to impaired cerebral oxygen and glucose metabolism, resulting in mitochondrial dysfunction, disruption of the blood–brain barrier (BBB), and neuronal cell death. Ultimately, this adversely affects the neurological prognosis of patients with out-of-hospital cardiac arrest (OHCA). During this series of events, lactate levels increase, which can be useful in predicting the prognosis of patients with OHCA. Specifically, cerebrospinal fluid (CSF) lactate measured 24 h after return of spontaneous circulation (ROSC) has been shown to have a better predictive performance for neurological prognosis than serum lactate levels5.
A previous study employed steroids as potential treatments for cerebral metabolism derangement; however, they have not been reported to significantly improve long-term neurological prognosis6. Nonetheless, as cerebral metabolism varies depending on the severity of OHCA, it is essential for future studies on cerebral metabolism derangement treatments to distinguish between cerebral ischemia and mitochondrial dysfunction based on the severity of OHCA7.
Jugular bulb (JB) microdialysis is a useful method for monitoring cerebral metabolism in patients with OHCA, reflecting brain damage8. However, one study has reported that CSF lactate, which reflects the anaerobic metabolism of cerebral glycolysis, is unrelated to serum lactate levels. Additionally, lactate levels measured in the internal jugular vein are similar to arterial lactate levels9,10. However, this study was conducted in animals, and it remains unclear which specific part of the internal jugular vein was used for measuring serum lactate.
Therefore, in this secondary analysis of the previous study7, we aimed to investigate the agreement between JB lactate levels obtained through a catheter located in JB and CSF lactate levels obtained through a lumbar catheter.
Materials and methods
Ethical approval and consent
This study was approved by Chungnam National University Hospital institutional Review Board (CNUH IRB 201907033003). All procedures and protocols were conducted in accordance with the Declaration of Helsinki and the International Conference of Harmonization and Good Clinical Practice guidelines. Written informed consent and approval for the donation of human materials and research on human medical ethics were obtained from the patient’s next of kin.
Study design and patients
This prospective observational cohort study was conducted from July 2021 to June 2023 at a single center and targeted adult patients with OHCA who underwent target temperature management (TTM) with a Glasgow Coma Scale (GCS) score of 8 or lower immediately after ROSC. The neurological prognosis of the patients was evaluated 6 months after ROSC via face-to-face interviews or structured telephone interviews using the Glasgow–Pittsburgh cerebral performance category (CPC) scale11. Good neurological prognosis was defined as CPC 1 and 2, whereas poor neurological prognosis was defined as CPC 3–5. Face-to-face or structured telephone interviews were conducted by an emergency physician who understood the study protocol. The exclusion criteria were as follows: (1) CA due to trauma; (2) TTM discontinued due to hemodynamic instability; (3) TTM not performed due to cerebral hemorrhage, active bleeding, poor neurologic status prior to CA, or known terminal illness; (4) severe cerebral edema, obliteration of the basal cisterns, or an intracranial mass on brain computed tomography; (5) ineligibility for lumbar puncture due to antiplatelet therapy, anticoagulation therapy, coagulopathy, platelet count less than 40,000/mL, or international normalized ratio > 1.512; (6) Extracorporeal membrane oxygenation provided; and (7) consent was not granted by the next of kin for this study. The following data were recorded: age, sex, presence of a witness at the time of the collapse, cardiopulmonary resuscitation (CPR) administered by the bystander, cardiac rhythm during the first monitoring, etiology of CA, time from collapse to CPR (no-flow time), time from CPR to ROSC (low-flow time), serum neuron specific enolase measured at 72 h after ROSC, Charlson comorbidity index, GCS scores immediately after ROSC, and CPC 6 months after ROSC. Contrast-enhanced magnetic resonance imaging was performed using a 3T scanner (Achieva3T, Philips Medical System, Andover, Netherlands) between 72 and 96 h after ROSC to evaluate the presence of BBB disruption.
TTM protocol
TTM was conducted using cooling devices (Arctic Sun® Energy Transfer Pads™, Medivance Corp., Louisville, KY), and core body temperature was monitored using esophageal and bladder thermometers. In cases where the cause of CA was of cardiac origin, and the patients exhibited a shockable rhythm, we maintained a target temperature of 36 °C for 24 h. For all other patients, we maintained a target temperature of 33 °C for 24 h. Afterward, patients were rewarmed at a rate of 0.25 °C/h up to 37 °C and then maintained at 37 °C for 72 h before discontinuing TTM.
Measurement of serum lactate obtained from the jugular bulb and CSF lactate
The right jugular vein was accessed through the retrograde insertion of a 22 G intravenous catheter (130 mm), with the tip placed in JB under ultrasound guidance. According to a previous study8, the placement of the JB catheter tip corresponds to the anatomical landmark at the level of the mastoid. The placement was confirmed using lateral cervical spine radiography (Fig. 1). A lumbar catheter was inserted using a Hermetic™ lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ) between the 3rd and 4th lumbar spine of the patient, who was lying in the lateral decubitus position with the hip and knee flexed. Arterial samples were collected using a radial arterial catheter. Samples obtained from the arterial, JB, and lumbar catheters were centrifuged at 3000 rpm for 10 min, and the supernatants were immediately analysed. Lactate levels were measured immediately, 24 h, 48 h, and 72 h after ROSC.
Figure 1.
The placement of the catheter tip confirmed using lateral cervical spine X-ray. Lateral cervical spine X-ray documented a correct positioning of the jugular bulb catheter tip (black circle).
Statistical analysis
We planned to enrol 40 patients in accordance with the inclusion and exclusion criteria, as there were no previous studies reporting agreement between JB and CSF lactate levels in patients with OHCA. Continuous variables are reported as medians with interquartile ranges or means and standard deviations, depending on the normal distribution. Categorical variables are reported as frequencies and percentages. Comparisons between the arterial, JB, and CSF lactate levels were made using the Wilcoxon signed-rank test, Kendall’s tau correlation analysis. We divided the lactate levels into intervals based on the interquartile range, and conducted a reliability analysis using using Cohen’s kappa to evaluate agreement between arterial, CSF, and JB lactate levels. All statistical analyses were performed using the PASW-SPSS software version 18 (IBM, Armonk, NY) and MedCalc 15.2.2 (MedCalc Software, Mariakerke, Belgium). Results were considered statistically significant at p < 0.05 (two-tailed).
Results
Patient characteristics
Of the 41 patients enrolled, 28 (68.3%) had poor neurological prognosis. Among the enrolled patients, 8 (19.5%), 5 (12.2%), 1 (2.4%), 2 (4.9%), and 25 (61.0%) had CPC values of 1, 2, 3, 4, and 5, respectively. Overall, 25 patients had a CPC score of 5; however, among them, 11 died during the study period, 2 died due to pneumonia, and organ donation was performed after brain death in 9 patients (Fig. 2). Regarding patients with witnessed CA and cardiac etiology, a higher number had a good neurological prognosis, whereas a longer low-flow time was associated with a poor neurological prognosis. In contrast-enhanced magnetic resonance imaging, 25 patients exhibited BBB disruption, and 23 (82.1%) out of 28 patients with a poor neurological prognosis showed BBB disruption (Table 1).
Figure 2.
Flowchart of the study. ROSC Return of spontaneous circulation, GCS Glasgow Coma Scale, ECMO Extracorporeal membrane oxygenation.
Table 1.
General characteristics.
| Variables | Total (n = 41) | Good (n = 13) | Poor (n = 28) | P value | |
|---|---|---|---|---|---|
| Age (years) | 58.29 ± 16.38 | 60.23 ± 11.33 | 57.39 ± 18.38 | 0.55 | |
| Sex, n (%) | Male | 30 (73.2) | 12 (92.3) | 18 (64.3) | 0.06 |
| Witness, n (%) | Yes | 24 (58.5) | 11 (84.6) | 13 (46.4) | 0.02 |
| Bystander CPR, n (%) | Yes | 28 (68.3) | 10 (76.9) | 18 (64.3) | 0.42 |
| Shockable rhythm, n (%) | Yes | 8 (19.5) | 4 (30.8) | 4 (14.3) | 0.22 |
| Cardiac etiology, n (%) | Yes | 18 (43.9) | 9 (69.2) | 9 (32.1) | 0.03 |
| No flow time (min) | 2.00 (0.00–13.50) | 1.00 (0.00–3.00) | 9.00 (0.00–19.50) | 0.07 | |
| Low flow time (min) | 25.50 (15.00–38.25) | 15.00 (9.50–23.50) | 28.00 (19.75–42.75) | 0.01 | |
| GCS | 3 (3.0–3.0) | 3 (3.0–3.5) | 3 (3.0–3.0) | 0.89 | |
| BBB disruption | Yes | 25 (61.0) | 2 (15.4) | 23 (82.1) | < 0.001 |
| Serum NSE72 | 60.00 (16.65–203.00) | 16.40 (13.05–26.55) | 108.20 (49.05–254.75) | < 0.001 | |
| CCI | 2.00 (1.00–4.00) | 3.00 (1.00–4.00) | 2.00 (0.25–4.00) | 0.88 | |
| Hypertension | 16 (39.0) | 5 (38.5) | 11 (39.3) | ||
| Diabetic mellitus | 13 (31.7) | 6 (46.2) | 7 (25.0) | ||
| Myocardial infarction | 5 (12.2) | 2 (15.4) | 3 (10.7) | ||
| Atrial fibrillation | 1 (2.4) | 1 (7.7) | 0 (0.0) | ||
| Lung disease | 4 (9.8) | 0 (0.0) | 4 (14.3) | ||
| Renal disease | 8 (19.5) | 3 (23.1) | 5 (17.9) |
Values are presented as number (%) for categorical variables and mean ± standard deviation or median (interquartile range) for continuous variables depending on normal distribution. A good neurological prognosis was defined as CPC 1 and 2, while a poor neurological prognosis was defined as CPC 3–5.
CPR Cardiopulmonary resuscitation, GCS Glasgow Coma Scale, BBB Blood–brain barrier, NSE72 Neuron specific enolase measured at 72 h after return of spontaneous circulation, CCI Charlson comorbidity index.
Comparison between arterial, JB, and CSF lactate levels
In patients with a good neurological prognosis, CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 3.40 (2.55–5.25), 2.20 (1.90–4.30), 2.30 (1.65–3.70), 2.10 (1.70–2.85), whereas JB lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 2.20 (1.80–3.15), 1.30 (0.95–2.25), 1.30 (0.70–1.65), 1.20 (0.70–1.65), (p = 0.002, 0.02, 0.001, and 0.02, respectively). In patients with a poor neurological prognosis, CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 6.15 (4.23–7.70), 4.15 (3.50–5.60), 3.65 (2.60–6.55), 3.15 (2.60–5.95), whereas JB lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 3.65 (2.13–5.40), 2.20 (1.63–4.38), 1.90 (1.33–3.20), 1.50 (1.30–1.98), (p = 0.009, < 0.001, < 0.001, and < 0.001, respectively) (Table 2).
Table 2.
Comparison between arterial, JB, and CSF lactate levels, with respect to neurological prognosis.
| JB and CSF lactate (mmol/L) | Overall | Good (n = 13) | Poor (n = 28) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Time | JB | CSF | P value | JB | CSF | P value | JB | CSF | P value |
| Immediately after ROSC | 3.00 (1.95–4.85) | 5.30 (3.35–6.80) | < 0.001 | 2.20 (1.80–3.15) | 3.40 (2.55–5.25) | 0.002 | 3.65 (2.13–5.40) | 6.15 (4.23–7.70) | 0.01 |
| 24 h after ROSC | 2.00 (1.30–2.95) | 4.00 (2.45–5.15) | < 0.001 | 1.30 (0.95–2.25) | 2.20 (1.90–4.30) | 0.02 | 2.20 (1.63–4.38) | 4.15 (3.50–5.60) | < 0.001 |
| 48 h after ROSC | 1.60 (1.10–2.15) | 3.40 (2.30–5.60) | < 0.001 | 1.30 (0.70–1.65) | 2.30 (1.65–3.70) | 0.001 | 1.90 (1.33–3.20) | 3.65 (2.60–6.55) | < 0.001 |
| 72 h after ROSC | 1.40 (1.15–1.90) | 2.90 (2.15–5.70) | < 0.001 | 1.20 (0.70–1.65) | 2.10 (1.70–2.85) | 0.02 | 1.50 (1.30–1.98) | 3.15 (2.60–5.95) | < 0.001 |
| Arterial and JB lactate (mmol/L) | Overall | Good (n = 13) | Poor (n = 28) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Time | Arterial | JB | P value | Arterial | JB | P value | Arterial | JB | P value |
| Immediately after ROSC | 3.30 (2.10–5.00) | 3.00 (1.95–4.85) | 0.48 | 2.10 (1.65–2.65) | 2.20 (1.80–3.15) | 0.25 | 4.00 (2.93–7.63) | 3.65 (2.13–5.40) | 0.15 |
| 24 h after ROSC | 1.90 (1.25–3.40) | 2.00 (1.30–2.95) | 0.54 | 1.20 (0.95–1.65) | 1.30 (0.95–2.25) | 0.42 | 2.30 (1.60–4.63) | 2.20 (1.63–4.38) | 0.25 |
| 48 h after ROSC | 1.60 (1.15–2.20) | 1.60 (1.10–2.15) | 0.24 | 1.30 (0.80–1.75) | 1.30 (0.70–1.65) | 0.23 | 1.95 (1.43–3.20) | 1.90 (1.33–3.20) | 0.48 |
| 72 h after ROSC | 1.60 (1.20–2.15) | 1.40 (1.15–1.90) | 0.20 | 0.90 (0.75–1.75) | 1.20 (0.70–1.65) | 0.35 | 1.80 (1.33–2.20) | 1.50 (1.30–1.98) | 0.02 |
| Arterial and CSF lactate (mmol/L) | Overall | Good (n = 13) | Poor (n = 28) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Time | Arterial | CSF | P value | Arterial | CSF | P value | Arterial | CSF | P value |
| Immediately after ROSC | 3.30 (2.10–5.00) | 5.30 (3.35–6.80) | 0.003 | 2.10 (1.65–2.65) | 3.40 (2.55–5.25) | 0.002 | 4.00 (2.93–7.63) | 6.15 (4.23–7.70) | 0.10 |
| 24 h after ROSC | 1.90 (1.25–3.40) | 4.00 (2.45–5.15) | < 0.001 | 1.20 (0.95–1.65) | 2.20 (1.90–4.30) | 0.01 | 2.30 (1.60–4.63) | 4.15 (3.50–5.60) | 0.001 |
| 48 h after ROSC | 1.60 (1.15–2.20) | 3.40 (2.30–5.60) | < 0.001 | 1.30 (0.80–1.75) | 2.30 (1.65–3.70) | 0.002 | 1.95 (1.43–3.20) | 3.65 (2.60–6.55) | < 0.001 |
| 72 h after ROSC | 1.60 (1.20–2.15) | 2.90 (2.15–5.70) | < 0.001 | 0.90 (0.75–1.75) | 2.10 (1.70–2.85) | 0.003 | 1.80 (1.33–2.20) | 3.15 (2.60–5.95) | < 0.001 |
Data are presented as median values (interquartile ranges).
CSF Cerebrospinal fluid, JB Jugular bulb.
Correlation between JB lactate levels and CSF lactate levels
In patients with a good neurological prognosis, the correlations coefficient between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.41, 0.26, 0.31, − 0.03 (p = 0.06, 0.22, 0.16, and 0.90, respectively). However, in patients with a poor neurological prognosis, the correlations coefficient between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.53, 0.38, 0.34, 0.29 (p < 0.001, 0.01, 0.01, and 0.04, respectively) (Fig. 3).
Figure 3.
Correlation between jugular bulb (JB) lactate levels and cerebrospinal fluid (CSF) lactate levels, in the context of neurological prognosis, is as follows: For patients with a good neurological prognosis, there were no significant correlations between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC. However, in patients with a poor neurological prognosis, significant correlations between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were observed. ROSC Return of spontaneous circulation, CC Correlation coefficient, JB Jugular bulb, CSF Cerebrospinal fluid.
The agreement between arterial, JB, and CSF lactate levels
In patients with a good neurological prognosis, kappa between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.08, 0.36, 0.14, − 0.05 (p = 0.65, 0.06, 0.48, and 0.75, respectively). However, in patients with a poor neurological prognosis, kappa between JB and CSF lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.38, 0.21, 0.22, 0.12 (p = 0.001, 0.04, 0.04, and 0.27, respectively). In patients with a good neurological prognosis, kappa between JB and arterial lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.33, 0.88, 0.64, 0.54 (p = 0.04, < 0.001, 0.001, and 0.001, respectively) (Table 3). In patients with a poor neurological prognosis, kappa between JB and arterial lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC were 0.42, 0.66, 0.85, 0.52 (p < 0.001, < 0.001, < 0.001, and < 0.001, respectively) (Table 3).
Table 3.
Agreement between arterial, JB, and CSF lactate levels, in relation to neurological prognosis.
| JB and CSF lactate | Overall | Good | Poor | |||
|---|---|---|---|---|---|---|
| Time | Kappa | P value | Kappa | P value | Kappa | P value |
| Immediately after ROSC | 0.32 | < 0.001 | 0.08 | 0.65 | 0.38 | 0.001 |
| 24 h after ROSC | 0.32 | < 0.001 | 0.36 | 0.06 | 0.21 | 0.04 |
| 48 h after ROSC | 0.25 | 0.01 | 0.14 | 0.48 | 0.22 | 0.04 |
| 72 h after ROSC | 0.12 | 0.18 | − 0.05 | 0.75 | 0.12 | 0.27 |
| Arterial and JB lactate | Overall | Good | Poor | |||
|---|---|---|---|---|---|---|
| Time | Kappa | P value | Kappa | P value | Kappa | P value |
| Immediately after ROSC | 0.42 | < 0.001 | 0.33 | 0.04 | 0.42 | < 0.001 |
| 24 h after ROSC | 0.74 | < 0.001 | 0.88 | < 0.001 | 0.66 | < 0.001 |
| 48 h after ROSC | 0.81 | < 0.001 | 0.64 | 0.001 | 0.85 | < 0.001 |
| 72 h after ROSC | 0.55 | < 0.001 | 0.54 | 0.001 | 0.52 | < 0.001 |
| Arterial and CSF lactate | Overall | Good | Poor | |||
|---|---|---|---|---|---|---|
| Time | Kappa | P value | Kappa | P value | Kappa | P value |
| Immediately after ROSC | 0.42 | < 0.001 | 0.50 | 0.01 | 0.31 | 0.01 |
| 24 h after ROSC | 0.31 | 0.001 | 0.49 | 0.05 | 0.15 | 0.21 |
| 48 h after ROSC | 0.29 | 0.001 | 0.39 | 0.05 | 0.18 | 0.10 |
| 72 h after ROSC | 0.12 | 0.18 | 0.04 | 0.83 | 0.07 | 0.55 |
CSF Cerebrospinal fluid, JB Jugular bulb.
Discussion
In this study, CSF lactate levels were higher than JB lactate levels, and a statistically significant agreement was observed between CSF and JB lactate levels in patients with a poor neurological prognosis compared to those with a good neurological prognosis. Based on the small number of patients with a good neurological prognosis, it remains difficult to make strong statements regarding the relationship observed between JB lactate and CSF lactate levels in patients with a poor neurological prognosis compared to those with a good neurological prognosis (supple 1). In South Korea, euthanasia is not recognized, and even with a CPC score of 5, life-sustaining treatment is continued if consent for the withdrawal of life-sustaining treatment is not granted by the next of kin. Of the 25 patients with CPC scores of 5, 11 died during the study period.
Lactate is slowly transported across the BBB via passive transport. Therefore, CSF lactate reflects the anaerobic metabolism of cerebral glycolysis, independent of serum lactate10. Previous studies have demonstrated that the severity of BBB disruption correlates with a poor neurological prognosis in patients with OHCA, and the prognostic performance of serum NSE varies based on BBB disruption13–15. In this study using contrast-enhanced magnetic resonance imaging to evaluate BBB disruption, 23 (82.1%) out of 28 patients with poor neurological prognosis showed BBB disruption, and it can be inferred that the agreement between CSF lactate and JB lactate in patients with poor outcomes may be related to BBB disruption. However, further investigation is required to substantiate this hypothesis. Additionally, JB lactate levels measured immediately, at 24 h, 48 h, and 72 h after ROSC exhibited agreement with arterial lactate levels, irrespective of the neurological prognosis. This could be attributed to the JB catheter's inability to reach the lateral venous sinus, where it meets the jugular fossa. This limitation may pose drawbacks for brain metabolism monitoring using JB catheters. Therefore, utilizing JB catheters for brain metabolism monitoring in OHCA patients may have its limitations.
Serum lactate levels tended to increase immediately after ROSC and gradually decreased over time5,16. In this study, even among patients with a poor neurological prognosis, there was no agreement between JB and CSF lactate levels measured at 72 h after ROSC, indicating a decrease in serum lactate levels over time following ROSC in patients with OHCA.
In patients with OHCA, lactate levels can increase; however, the mechanisms underlying cerebral ischemia and mitochondrial dysfunction differ. Cerebral ischemia occurs due to a relative insufficiency in the supply of oxygen and glucose compared to cerebral demands. In contrast, mitochondrial dysfunction results in an increase in lactate levels despite a sufficient oxygen and glucose supply17–21. Cerebral ischemia and reperfusion-induced mitochondrial dysfunction lead to cellular apoptosis, yet its mechanism is highly complex. Impairment in endoplasmic reticulum-mitochondrial calcium transfer is a primary cause. Reactive oxygen species, free radicals, and inflammatory mediators contribute to mitochondrial damage, resulting in decreased cellular respiration and ultimately leading to cellular apoptosis22–25.
Although this was an animal study, treatments such as nitrite therapy, which differ from ischemia-related interventions, are effective in treating mitochondrial dysfunction26,27. Nonetheless, several clinical studies5,6 have reported that steroid therapy does not improve neurological prognosis in patients with OHCA. In a study investigating the impact of mean arterial blood pressure regulation on the neurological prognosis of OHCA patients through JB based brain metabolism monitoring, lactate/pyruvate ratio exceeding 16 was defined as ischemia when pyruvate is below 70 μM, and exceeding 70 μM was defined as mitochondrial dysfunction. The study reported that mean arterial blood pressure regulation does not improve neurological prognosis in patients with OHCA28. In this study, no significant agreement was observed between CSF and JB lactate levels in patients with a good neurological prognosis. Consequently, when neurological prognostic indicators suggest that patients with OHCA are likely to have a good neurological prognosis through several scoring systems, imaging modalities, and biomarkers used to predict the neurological prognosis of patients with OHCA29–31, considering the limitations of differentiating between cerebral ischemia and mitochondrial dysfunction using JB lactate is crucial.
This study had several limitations. First, this was a single-center study with a small sample size. Second, we did not continuously assess JB and CSF lactate levels. However, JB and CSF samples were obtained using inserted catheters, and there was no time difference in the collection of these samples. Finally, the parameters were measured until 72 h after ROSC; thus, changes in the parameters over a long duration could not be determined. Further studies are necessary to overcome these limitations.
Conclusions
This study demonstrated that JB lactate levels exhibited significant agreement with arterial lactate levels, compared to CSF lactate levels. Therefore, this should be considered when using JB lactate to monitor cerebral metabolism.
Supplementary Information
Author contributions
All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the Resuscitation. Please indicate the specific contributions made by each author. The name of each author must appear at least once in each of the three categories below. Conceptualization, writing (review and editing): Y.Y. Investigation, writing (original draft), and funding acquisition: J.S.P. Methodology and project administration: C.K. Resources and software: W.J. Formal analysis: H.J.A. Supervision and validation: J.H.M. Visualization and design of the work: Y.N.I. Data curation and interpretation: S.Y.J. Approval of the version of the manuscript to be published (the names of all authors must be listed): Y.Y., J.S.P., J.H.M., W.J., H.J.A., Y.N.I., C.K., S.Y.J.
Funding
Funding was provided by Chungnam National University Hospital Research Fund 2020.
Data availability
Data is provided within the manuscript or supplementary information files.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-024-59986-5.
References
- 1.Madathil RJ, et al. Ischemia reperfusion injury as a modifiable therapeutic target for cardioprotection or neuroprotection in patients undergoing cardiopulmonary resuscitation. Resuscitation. 2016;105:85–91. doi: 10.1016/j.resuscitation.2016.04.009. [DOI] [PubMed] [Google Scholar]
- 2.Takahashi M, Macdonald RL. Vascular aspects of neuroprotection. Neurol. Res. 2004;26:862–869. doi: 10.1179/016164104X3815. [DOI] [PubMed] [Google Scholar]
- 3.Huang L, et al. A systematic review of neuroprotective strategies after cardiac arrest: From bench to bedside (part II-comprehensive protection) Med. Gas Res. 2014;4:10. doi: 10.1186/2045-9912-4-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Park JS, et al. Study on the timing of severe blood-brain barrier disruption using cerebrospinal fluid-serum albumin quotient in post cardiac arrest patients treated with targeted temperature management. Resuscitation. 2019;135:118–123. doi: 10.1016/j.resuscitation.2018.10.026. [DOI] [PubMed] [Google Scholar]
- 5.Son SH, et al. Cerebrospinal fluid lactate levels, brain lactate metabolism and neurologic outcome in patients with out-of-hospital cardiac arrest. Neurocrit. Care. 2021;35:262–270. doi: 10.1007/s12028-020-01181-1. [DOI] [PubMed] [Google Scholar]
- 6.Obling LE, et al. Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): A randomized clinical trial. Intensive Care Med. 2023;49(12):1467–1478. doi: 10.1007/s00134-023-07247-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.You Y, et al. Differences in cerebral metabolism between moderate- and high-severity groups of patients with out-of-hospital cardiac arrest undergoing target temperature management. Brain Sci. 2023;13:1373. doi: 10.3390/brainsci13101373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mölström S, et al. Bedside microdialysis for detection of early brain injury after out-of-hospital cardiac arrest. Sci. Rep. 2021;11:15871. doi: 10.1038/s41598-021-95405-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Posner JB, Plum F. Independence of blood and cerebrospinal fluid lactate. Arch. Neurol. 1967;16:492–496. doi: 10.1001/archneur.1967.00470230044005. [DOI] [PubMed] [Google Scholar]
- 10.Hladky SB, Barrand MA. Elimination of substances from the brain parenchyma: Efflux via perivascular pathways and via the blood-brain barrier. Fluids Barriers CNS. 2018;15:30. doi: 10.1186/s12987-018-0113-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Longstreth WT, Jr, Nichol G, Van Ottingham L, Hallstrom AP. Two simple questions to assess neurologic outcomes at 3 months after out-of-hospital cardiac arrest: Experience from the public access defibrillation trial. Resuscitation. 2010;81:530–533. doi: 10.1016/j.resuscitation.2010.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Engelborghs S, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement. 2017;8:111–126. doi: 10.1016/j.dadm.2017.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jeon GR, et al. The association between neurological prognosis and the degree of blood-brain barrier disruption in cardiac arrest survivors who underwent target temperature management. Neurocrit. Care. 2021;35:815–824. doi: 10.1007/s12028-021-01241-0. [DOI] [PubMed] [Google Scholar]
- 14.Lee S, et al. Comparison of intracranial pressure changes in out-of-hospital cardiac arrest patients with and without malignant blood-brain barrier disruption. Clin. Exp. Emerg. Med. 2022;9:296–303. doi: 10.15441/ceem.22.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kang C, et al. Blood-brain barrier disruption as a cause of various serum neuron-specific enolase cut-off values for neurological prognosis in cardiac arrest patients. Sci. Rep. 2022;12:2186. doi: 10.1038/s41598-022-06233-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Laurikkala J, et al. Early lactate values after out-of-hospital cardiac arrest: Associations with one-year outcome. Shock. 2019;51:168–173. doi: 10.1097/SHK.0000000000001145. [DOI] [PubMed] [Google Scholar]
- 17.Neumar RW, et al. Post cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation. 2008;118:2452–2483. doi: 10.1016/j.resuscitation.2008.09.017. [DOI] [PubMed] [Google Scholar]
- 18.Kim JC, et al. Association between lactate clearance during post-resuscitation care and neurologic outcome in cardiac arrest survivors treated with targeted temperature management. Clin. Exp. Emerg. Med. 2017;30:10–18. doi: 10.15441/ceem.16.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Nielsen TH, et al. Cererbral energy metabolism during induced mitochondrial dysfunction. Acta Anaesthesiol. Scand. 2013;57:229–235. doi: 10.1111/j.1399-6576.2012.02783.x. [DOI] [PubMed] [Google Scholar]
- 20.Nielsen TH, Olsen NV, Toft P, Nordström CH. Cerebral energy metabolism during mitochondrial dysfunction induced by cyanide in piglets. Acta Anaesthesiol. Scand. 2013;57:793–801. doi: 10.1111/aas.12092. [DOI] [PubMed] [Google Scholar]
- 21.Larach DB, Kofke A, Le Roux P. Potential non-hypoxic/ischemic causes of increase cerebral interstitial fluid lactate/pyruvate ratio: A review of available litterature. Neurocrit. Care. 2011;15:609–622. doi: 10.1007/s12028-011-9517-8. [DOI] [PubMed] [Google Scholar]
- 22.Ouyang YB, Kuroda S, Kristián T, Siesjö BK. Release of mitochondrial aspartate aminotransferase (mAST) following transient focal cerebral ischemia suggests the opening of a mitochondrial permeability transition pore. Neurosci. Res. Commun. 1997;20(3):167–173. doi: 10.1002/(SICI)1520-6769(199705)20:3<167::AID-NRC198>3.0.CO;2-3. [DOI] [Google Scholar]
- 23.Ouyang YB, Tan Y, Comb M, Liu CL, Martone ME, Siesjö BK, Hu BR. Survival- and death-promoting events after transient cerebral ischemia: Phosphorylation of Akt, release of cytochrome C, and activation of caspase-like proteases. J. Cereb. Blood Flow Metabol. 1999;19(10):1126–1135. doi: 10.1097/00004647-199910000-00009. [DOI] [PubMed] [Google Scholar]
- 24.Gouriou Y, Demaurex N, Bijlenga P, de Marchi U. Mitochondrial calcium handling during ischemia-induced cell death in neurons. Biochimie. 2011;93(12):2060–2067. doi: 10.1016/j.biochi.2011.08.001. [DOI] [PubMed] [Google Scholar]
- 25.Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front. Neurosci. 2021;15:689938. doi: 10.3389/fnins.2021.689938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dezfulian C, et al. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. Circulation. 2009;120:897–905. doi: 10.1161/CIRCULATIONAHA.109.853267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Katz A, Brosnahan SB, Papadopoulos J, Parnia S, Lam JQ. Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest. Ann. N. Y. Acad. Sci. 2022;1507:49–59. doi: 10.1111/nyas.14613. [DOI] [PubMed] [Google Scholar]
- 28.Mølstrøm S, et al. A randomized, double-blind trial comparing the effect of two blood pressure targets on global brain metabolism after out-of-hospital cardiac arrest. Crit. Care. 2023;27(1):73. doi: 10.1186/s13054-023-04376-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pham V, et al. Performance of OHCA, NULL-PLEASE and CAHP scores to predict survival in Out-of-Hospital Cardiac Arrest due to acute coronary syndrome. Resuscitation. 2021;166:31–37. doi: 10.1016/j.resuscitation.2021.07.011. [DOI] [PubMed] [Google Scholar]
- 30.Lee S, et al. Preliminary prognostication for good neurological outcomes in the early stage of post-cardiac arrest care. Diagnostics (Basel) 2023;26:2174. doi: 10.3390/diagnostics13132174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Sandroni C, D’Arrigo S, Nolan JP. Prognostication after cardiac arrest. Crit. Care. 2018;22:150. doi: 10.1186/s13054-018-2060-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data is provided within the manuscript or supplementary information files.